Table 2.
Significant and nonsignificant prognostic markers on univariate analysis
| Factor | HR | Lower 95% | Upper 95% | P‐value |
|---|---|---|---|---|
| Age | 1.02 | 1.001 | 1.038 | 0.0391 |
| Male gender | 1.20 | 0.820 | 1.764 | 0.3498 |
| Race | ||||
| Caucasian (reference) | ||||
| African American | 0.88 | 0.441 | 1.600 | 0.6972 |
| Hispanic | 1.08 | 0.525 | 1.991 | 0.8166 |
| Other/Unknown | 2.19 | 0.845 | 4.646 | 0.0995 |
| Insurance | ||||
| Private (reference) | ||||
| Medicare | 1.90 | 1.207 | 2.930 | 0.0062 |
| Medicaid | 1.54 | 0.809 | 2.726 | 0.1773 |
| Charlson Comorbidity Index | 1.26 | 1.172 | 1.355 | <0.0001 |
| Cirrhosis | 1.54 | 0.978 | 2.361 | 0.0618 |
| Viral hepatitis | 0.93 | 0.517 | 1.601 | 0.7935 |
| Child Pugh class | ||||
| A (reference) | ||||
| B/C | 2.84 | 1.758 | 4.437 | <0.0001 |
| MELD | 1.08 | 1.046 | 1.102 | <0.0001 |
| AJCC stage | ||||
| I (reference) | ||||
| II | 2.14 | 0.934 | 5.543 | 0.0727 |
| III | 2.58 | 0.900 | 7.598 | 0.0770 |
| IV | 6.39 | 2.88 | 16.49 | <0.0001 |
| Tumor size | 1.11 | 1.045 | 1.177 | 0.0005 |
| Tumor location | ||||
| Unilobar (reference) | ||||
| Bilobar | 2.30 | 1.542 | 3.437 | <0.0001 |
| Multifocal Tumor | 2.31 | 1.547 | 3.486 | <0.0001 |
| Vascular invasion | 1.74 | 0.906 | 3.485 | 0.0968 |
| Extrahepatic metastases | 2.97 | 1.970 | 4.514 | <0.0001 |
| Treatment | ||||
| Resection (reference) | ||||
| IO | 1.76 | 0.703 | 4.113 | 0.2156 |
| Systemic | 5.62 | 3.070 | 11.063 | <0.0001 |
| Supportive | 21.71 | 10.674 | 45.836 | <0.0001 |
| ANC (continuous) | 1.14 | 1.067 | 1.2016 | 0.0001 |
| ALC (continuous) | 0.58 | 0.403 | 0.811 | 0.0013 |
| Platelets (continuous) | 1.00 | 0.998 | 1.002 | 0.8154 |
| log(NLR) | 2.11 | 1.555 | 2.847 | <0.0001 |
| log(PLR) | 1.43 | 1.007 | 2.036 | 0.0454 |
| log(SII) | 1.38 | 1.106 | 1.732 | 0.0043 |
Abbreviations: AJCC, American Joint Committee on Cancer; ALC, absolute lymphocyte count; ANC, absolute neutrophil count; IO, interventional oncology; MELD, Model for End‐stage Liver Disease; NLR, neutrophil‐to‐lymphocyte ratio; PLR, platelet‐to‐lymphocyte ratio; SII, systemic immune‐inflammation index.